3- to 24-month Follow-up on COVID-19 with Pulmonary Tuberculosis Survivors after Discharge: Results from a Prospective, Multicenter Study
- Author:
Ya Jing WANG
1
;
Yu Xing ZONG
;
Hui Gui WU
;
Lin Yuan QI
;
Zhen Hui LI
;
Yu Xin JI
;
Lin TONG
;
Lei ZHANG
;
Bo Ming YANG
;
Ye Pu YANG
;
Ke Ji LI
;
Rong Fu XIAO
;
Song Lin ZHANG
;
Hong Yun HU
;
De Hong LIU
;
Fang Shou XU
;
Sheng SUN
;
Wei WU
;
Ya MAO
;
Qing Min LI
;
Hua Hao HOU
;
Yuan Zhao GONG
;
Yang GUO
;
Wen Li JIAO
;
Jin QIN
;
Yi Ding WANG
;
Fang WANG
;
Li GUAN
;
Gang LIN
;
Yan MA
;
Ping Yan WANG
;
Nan Nan SHI
Author Information
- Keywords: COVID-19; Pulmonary tuberculosis; Long-term; Sequela; Recurrence; Re-positive
- From: Biomedical and Environmental Sciences 2022;35(12):1091-1099
- CountryChina
- Language:Chinese
- Abstract: Objective Coronavirus disease 2019 (COVID-19) and tuberculosis (TB) are major public health and social issues worldwide. The long-term follow-up of COVID-19 with pulmonary TB (PTB) survivors after discharge is unclear. This study aimed to comprehensively describe clinical outcomes, including sequela and recurrence at 3, 12, and 24 months after discharge, among COVID-19 with PTB survivors. Methods From January 22, 2020 to May 6, 2022, with a follow-up by August 26, 2022, a prospective, multicenter follow-up study was conducted on COVID-19 with PTB survivors after discharge in 13hospitals from four provinces in China. Clinical outcomes, including sequela, recurrence of COVID-19, and PTB survivors, were collected via telephone and face-to-face interviews at 3, 12, and 24 months after discharge. Results Thirty-two COVID-19 with PTB survivors were included. The median age was 52 (45, 59) years, and 23 (71.9％) were men. Among them, nearly two-thirds (62.5％) of the survivors were moderate, three (9.4％) were severe, and more than half (59.4％) had at least one comorbidity (PTB excluded). The proportion of COVID-19 survivors with at least one sequela symptom decreased from 40.6％ at 3 months to 15.8％ at 24 months, with anxiety having a higher proportion over a follow-up. Cough and amnesia recovered at the 12-month follow-up, while anxiety, fatigue, and trouble sleeping remained after 24 months. Additionally, one (3.1％) case presented two recurrences of PTB and no re-positive COVID-19 during the follow-up period. Conclusion The proportion of long symptoms in COVID-19 with PTB survivors decreased over time, while nearly one in six still experience persistent symptoms with a higher proportion of anxiety. The recurrence of PTB and the psychological support of COVID-19 with PTB after discharge require more attention.
